<DOC>
	<DOCNO>NCT01323647</DOCNO>
	<brief_summary>This study aim evaluate persistence anti-poliovirus antibody toddler age 18 month prim oral polio vaccine ( OPV ) inactivate polio vaccine ( IPV ) primary study . The study also assess immunogenicity reactogenicity booster dose IPV subject prim three dos IPV .</brief_summary>
	<brief_title>Immunogenicity Safety Booster Dose PoliorixTM Vaccine Previously Vaccinated Toddlers</brief_title>
	<detailed_description>All subject also receive booster dose GSK Biologicals ' DTPa/Hib vaccine ( Infanrix+Hib ) Day 0 . This vaccine provide part local standard care associate study endpoint .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . Subjects receive complete threedose primary vaccination course study NCT01021293 . Healthy male female toddler 18 24 month age time Visit 1 ( Day 0 ) . Written inform consent obtain parent ( ) / Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede booster dose study vaccine ( ) , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior Visit 1 ( Day 0 ) . Administration immunoglobulins and/or blood product within 3 month precede Visit 1 ( Day 0 ) plan administration study period . Administration vaccine foreseen study protocol within 30 day Visit 1 ( Day 0 ) plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous booster vaccination poliomyelitis disease since conclusion visit Study NCT01021293 . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IPV</keyword>
	<keyword>PoliorixTM</keyword>
	<keyword>China</keyword>
</DOC>